Solutol hs

Manufactured by Merck Group

Sourced in Germany

Solutol HS is a non-ionic solubilizing agent produced by Merck Group. It is a polyethylene glycol derivative used to enhance the solubility and stability of various pharmaceutical and chemical formulations.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Solutol (17 citations) Solutol (Kolliphor) HS 15 (2 citations)

4 protocols using solutol hs

Defactinib Treatment and Helicobacter Infection in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Male mice aged 8–11 weeks were free of known intestinal pathogens and negative for Helicobacter species. Animals from each experimental group were cohoused. On days 0, 1 and 2, mice were injected i.v. with 1 mg/kg defactinib or vehicle (5% DMSO, 2.5% Solutol HS (Sigma), 2.5% absolute ethanol, 90% Dulbecco’s PBS). Daily, starting from day 3, mice were injected i.p. with 5 mg/kg defactinib or vehicle. 30 min after the initial i.v. injection, mice were infected with 1 × 10⁸ colony forming units Hh on days 0 and 1 by oral gavage with a 22 G curved, blunted needle (Popper & Sons). Mice were injected intraperitoneally once on day 0 with 1 mg anti-IL10R blocking antibody (clone 1B1.2). Infected mice were monitored daily for colitis symptoms. Mice were euthanized with CO₂ at d7 post infection, and organs were harvested for analysis. Experimental groups consisted of 5–7 co-housed mice and were blinded to the researchers.

Ryzhakov G., Almuttaqi H., Corbin A.L., Berthold D.L., Khoyratty T., Eames H.L., Bullers S., Pearson C., Ai Z., Zec K., Bonham S., Fischer R., Jostins-Dean L., Travis S.P., Kessler B.M, & Udalova I.A. (2021). Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. Nature Communications, 12, 6702.

+ Open protocol

+ Expand

Evaluating 8430 Anticancer Efficacy

Check if the same lab product or an alternative is used in the 5 most similar protocols

8430 was formulated in a mixed solution containing N-Methyl-2-pyrolidone (NMP, Sigma Aldrich, 328634), PEG400 (Sigma Aldrich, 202398) and 30% Solutol^® HS 15 w/w in water (Sigma Aldrich, 42966), in a 1:2:3 ratio. NMP, PEG400 and Solutol^® HS 15 mixed solvent was used as vehicle control. 8430 was introduced to 4^th mammary fat pad of CD-1 mice at 0 (vehicle), 15, 20 and 25 mg/kg every other day for three continuous weeks. Animal weight was measured every week. In addition, animals were euthanized, both gross and histopathological evaluation was performed, including histological assessment of liver, heart, pancreas, small and large intestine tissues by a board-certified veterinary pathologist (DR) at the Comparative Pathology Laboratory at Flint Animal Cancer Center, Colorado State University.

Zhou H., Blevins M.A., Hsu J.Y., Kong D., Galbraith M.D., Goodspeed A., Culp-Hill R., Oliphant M.U., Ramirez D., Zhang L., Pineiro J.T., Griner L.M., King R., Barnaeva E., Hu X., Southall N.T., Ferrer M., Gustafson D.L., Regan D.P., D’Alessandro A., Costello J.C., Patnaik S., Marugan J., Zhao R, & Ford H.L. (2020). A SIX1/EYA2 small molecule inhibitor disrupts EMT and metastasis. Cancer research, 80(12), 2689-2702.

+ Open protocol

+ Expand

Thymoquinone-Based Nanoemulsion Formulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Thymoquinone (99%) was obtained from UFC Biotechnology, (Buffalo, NY, USA). Oleic acid, ethyl oleate, castor oil, isopropyl myristate, isopropyl alcohol, sesame oil, PEG 400, tween 20, tween 80, and Kolliphor EL, Solutol HS were purchased from Sigma Aldrich (Hamburg, Germany), Black seed oil was purchased from Amazing Herbs, (Buford GA, USA). Caproyl 90 and Transcutol HP were purchased from Gattefosse (Saint-Proest France), Carbopol-940 was obtained from Lubrizol (Wickliffe, OH, USA). All other excipients were of pharmaceutical-grade reagent.

Algahtani M.S., Ahmad M.Z., Shaikh I.A., Abdel-Wahab B.A., Nourein I.H, & Ahmad J. (2021). Thymoquinone Loaded Topical Nanoemulgel for Wound Healing: Formulation Design and In-Vivo Evaluation. Molecules, 26(13), 3863.

+ Open protocol

+ Expand

SPOP Mutation Impacts Prostate Cancer Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols

Aliquots of 5 × 10 6 human C4-2b-pLenti-HA-SPOPF133V or C4-2b-pLenti-EV (SPOPwt control) prostate cancer cells in 100 μL (1:1, PBS:Matrigel ® ) were subcutaneously injected into the right flanks of 5-week-old male SCID mice (Charles River Lab, Wilmington, MA). Tumors were allowed to grow until they reached 60 to 70 mm 3 before they were randomly distributed to receive one of the following treatments orally for 18 days: talazoparib (0.33 mg/kg 5 days/week) or vehicle control buffer [10% dimethyacetamide (Sigma), 6% solutol HS (Sigma), 84% PBS]. Tumor volume was measured twice/week using calipers and calculated on the basis of (width x width x length)/2, as previously described (13, (link)23, (link)24) (link). Eighteen days after the initial treatment, the tumors were harvested. All animal experiments were conducted in accordance with accepted standards of humane animal care approved by the MDACC Institutional Animal Care and Use Committee.

Geng C., Zhang M.C., Manyam G.C., Vykoukal J.V., Fahrmann J.F., Peng S., Wu C., Park S., Kondraganti S., Wang D., Robinson B.D., Loda M., Barbieri C.E., Yap T.A., Corn P.G., Hanash S., Broom B.M., Pilié P.G, & Thompson T.C. (2023). SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(21).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!